[1]段桂姣,王振常,吴珊珊.柔肝化纤颗粒对肝纤维化模型大鼠肝组织超氧化物歧化酶和丙二醛的影响[J].西部中医药,2022,35(04):30-34.[doi:10.12174/j.issn.2096-9600.2022.04.08]
　DUAN Guijiao,WANG Zhenchang,Wu Shanshan.Effects of Rougan Huaxian Granules on SOD and MDA in Liver Tissue of Rats with Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2022,35(04):30-34.[doi:10.12174/j.issn.2096-9600.2022.04.08]
点击复制

柔肝化纤颗粒对肝纤维化模型大鼠肝组织超氧化物歧化酶和丙二醛的影响
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
35
期数:
2022年04期
页码:
30-34
栏目:
出版日期:
2022-04-15

文章信息/Info

Title:
Effects of Rougan Huaxian Granules on SOD and MDA in Liver Tissue of Rats with Hepatic Fibrosis
作者:
段桂姣1, 王振常2, 吴珊珊1
1.广西玉林第一人民医院，广西 玉林 537000
2.广西国际壮医医院
Author(s):
DUAN Guijiao1, WANG Zhenchang2, Wu Shanshan1
1.Yulin City First People’s Hospital, Yulin 537000, China
2.Guangxi International Zhuang Medicine Hospital
关键词:
肝纤维化; 柔肝化纤颗粒; 超氧化物歧化酶; 丙二醛; 氧化应激
Keywords:
hepatic fibrosis; granules; SOD; MDA; oxidative stress
分类号:
R256.4
DOI:
10.12174/j.issn.2096-9600.2022.04.08
文献标志码:
A
摘要:
目的观察柔肝化纤颗粒对四氯化碳诱导的肝纤维化模型大鼠肝组织中超氧化物歧化酶（superoxide dismutase，SOD）和丙二醛（malondialdehyde，MDA）的影响。 方法选择50只SD大鼠，其中空白组12只，其余38只制备四氯化碳（CCl4）诱导的肝纤维化大鼠模型，造模后随机分为模型组、柔肝化纤组及秋水仙碱组，每组12只。各组给予对应药物灌胃，连续给药4周。检测大鼠血清谷丙转氨酶（alanine aminotransferase，ALT）、谷草转氨酶（aspartate transaminase，AST）水平，计算肝脏脏器指数。放射免疫法检测血清透明质酸（hyaluronic acid，HA）、层黏蛋白（laminin，LN）、Ⅲ型前胶原（Collagen Ⅲ protein，P3NP）、Ⅳ型胶原（Collagen IV，CⅣ）的水平。检测肝组织中SOD和MDA水平。HE染色法观察肝组织纤维化程度。 结果与模型组比较，柔肝化纤组大鼠血清中ALT、AST、HA、LN、P3NP、CⅣ水平显著降低（P＜0.05），肝脏组织中SOD水平升高（P＜0.05），MDA水平降低（P＜0.05），肝脏指数降低（P＜0.05）。柔肝化纤组大鼠肝组织结构明显改善，肝细胞脂肪变性减轻，少许炎性细胞浸润与假小叶形成。 结论柔肝化纤颗粒可以降低肝纤维化大鼠肝组织中SOD和MDA含量，通过发挥其抗氧化作用减轻CCl4诱导的肝纤维化程度。
Abstract:
ObjectiveTo observe the effects of Rougan Huaxian granules on SOD and MDA in liver tissue of rats with hepatic fibrosis induced by carbon tetrachloride (CCI4). MethodsFifty SD rats were chosen, among them, 12 ones were selected into the blank group, the remaining 38 rats were prepared into rat models with hepatic fibrosis induced by CCI4, after modeling, they were randomized into the model group, Rougan Huaxian granules group and colchicine group, with 12 ones in each group. Different groups were drenched with the corresponding medicine, administration for four consecutive weeks. To detect the levels of AST and ALT in rat serum, and to calculate liver organ index. To measure the levels of HA, LN, P3NP and CⅣ by radioimmunoassay (RIA). To measure the levels of SOD and MDA in liver tissue. To observe the degrees of hepatic fibrosis in liver tissue by HE staining method. ResultsCompared with the model group, the levels of ALT, AST, HA, LN, P3NP and CⅣ lowered significantly in Rougan Huaxian granules group (P<0.05), the levels of SOD raised in liver tissue (P<0.05), the levels of MDA decreased (P<0.05), liver index reduced (P<0.05). Structural improvements of liver tissue in Rougan Huaxian granules group were notable, hepatocyte steatosis reduced, a few inflammatory cells infiltrated and pseudolobule formed. ConclusionRougan Huaxian granules could cut down the contents of SOD and MDA, and relieve the degrees of CCI4-induced hepatic fibrosis by developing its antioxidation effects.

相似文献/References:

[1]于立友,汪龙德△,张晶,等.化纤保肝方治疗气滞血瘀型肝纤维化的临床研究*[J].西部中医药,2013,26(10):84.
　YU Liyou,WANG Longde,ZHANG Jing,et al.Clinical Study on HuaQian BaoGan Prescription in the Treatment for Hepatic Fibrosis of Qi Staganation and Blood Stasis Pattern[J].Western Journal of Traditional Chinese Medicine,2013,26(04):84.
[2]黄鸿娜,黄晶晶△,王振常,等.柔肝化纤颗粒治疗肝硬化脾功能亢进症的临床观察[J].西部中医药,2014,27(09):111.
[3]刘成,杨宗国,陆云飞,等.消黄方对大鼠胆汁淤积性肝纤维化的干预作用*[J].西部中医药,2012,25(11):14.
　LIU Cheng,YANG Zong-guo,LU Yun-fei,et al.Therapeutic Effects of XiaoHuangFang on Cholestatic Liver Fibrosis in Rats[J].Western Journal of Traditional Chinese Medicine,2012,25(04):14.
[4]郭守强.苦参碱对肝纤维化大鼠转化生长因子β1表达的影响[J].西部中医药,2014,27(06):13.
　GUO Shouqiang.The Effects of Matrine on the Expressions of TGF-β1 of the Rats with Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2014,27(04):13.
[5]闫雪华.恩替卡韦联合复方鳖甲软肝片治疗代偿期乙肝肝硬化疗效观察[J].西部中医药,2014,27(07):84.
　YAN Xuehua.Clinical Observation on Entecavir Combined with Compound BieJia RuanGan Tablets in Treating Decompensated Liver Cirrhosis of Hepatitis B[J].Western Journal of Traditional Chinese Medicine,2014,27(04):84.
[6]陈耀章,李根旺.冬虫夏草对心肝肾的保护作用研究[J].西部中医药,2016,29(04):127.
　CHEN Yaozhang,LI Genwang.Study on the Protective Effects of DongChong XiaCao to Heart, Liver and Kidney[J].Western Journal of Traditional Chinese Medicine,2016,29(04):127.
[7]张玉玲,闫雪华△,谢青.中药联合抗病毒药物治疗HBV所致肝纤维化的研究进展[J].西部中医药,2019,32(06):149.
　ZHANG Yuling,YAN Xuehua,XIE Qing.The Progress of Herbs Joined with Antiviral Drugs in the Treatment for HBV - induced Hepatic Fibrosis[J].Western Journal of Traditional Chinese Medicine,2019,32(04):149.
[8]徐俊,戚璐,许杰,等.抗纤软肝颗粒对肝纤维化小鼠肠道黏膜通透性的影响[J].西部中医药,2022,35(07):27.[doi:10.12174/j.issn.2096-9600.2022.07.07]
　XU Jun,QI Lu,XU Jie,et al.Influence of Anti-fibrosis Liver-softening Granules on Intestinal Mucosal Permeability in Hepatic Fibrosis Mice[J].Western Journal of Traditional Chinese Medicine,2022,35(04):27.[doi:10.12174/j.issn.2096-9600.2022.07.07]
[9]陈美岑,等.柔肝化纤颗粒对失代偿期肝硬化患者肠道菌群的影响[J].西部中医药,2021,34(12):99.[doi:10.12174/j.issn.2096-9600.2021.12.26]
　CHEN Meicen,WANG Zhenchang,et al.Effects of Rougan Huaxian Granules on Intestinal Flora in Patients with Decompensated Cirrhosis[J].Western Journal of Traditional Chinese Medicine,2021,34(04):99.[doi:10.12174/j.issn.2096-9600.2021.12.26]
[10]李莎,焦战,陈青,等.瞬时弹性成像技术评价自拟中药治疗肝纤维化的临床疗效[J].西部中医药,2020,33(08):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
　LI Sha,JIAO Zhan,CHEN Qing,et al.Clinical Effects of Selfmade Herbs in Treating Liver Fibrosis Evaluated by Transient Elastography[J].Western Journal of Traditional Chinese Medicine,2020,33(04):89.[doi:10.12174/j.issn.1004-6852.2020.08.23]
[11]吕艳杭,吴姗姗,王振常,等.柔肝化纤颗粒治疗乙肝肝硬化腹水的临床疗效及对肝纤维化、氧化应激水平的影响[J].西部中医药,2021,34(03):19.[doi:10.12174/j.issn.2096-9600.2021.03.05]
　LYU Yanhang,WU Shanshan,WANG Zhenchang,et al.Curative Effects of Rougan Huaxian Granules in Treating Ascites of Hepatitis B Cirrhosis and Its Influence on the Levels of Oxidative Stress and Liver Fibrosis[J].Western Journal of Traditional Chinese Medicine,2021,34(04):19.[doi:10.12174/j.issn.2096-9600.2021.03.05]

备注/Memo

备注/Memo:
段桂姣（1992—），女，硕士学位，住院医师。研究方向：肝纤维化、肝硬化的中西医结合基础与临床研究。国家自然科学基金（81660745，81960910）。
更新日期/Last Update: 2022-06-24